On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

200 Years of Hodgkin Lymphoma

This year’s ASH Education Program features a look at the progress that has been made in the two centuries since Thomas Hodgkin entered medicine....

Education Program Preview

Interview with Education Program Co-Chairs Elisabeth Battinelli, MD, PhD, and Jason Gotlib, MD, MS What are your goals for this year’s education program? Dr. Gotlib: We...

Scientific Program Preview

Interview with Scientific Program Co-Chairs Robert Flaumenhaft, MD, PhD, and Charles Mullighan, MBBS (Hons), MD What are your goals for this year’s scientific program? Dr. Flaumenhaft:...

A Global Perspective on Chronic Myeloid Leukemia

In the U.S. and other high-income countries, access to testing and first-, second-, and third-generation tyrosine kinase inhibitors has improved the management and prognosis...

Drug Problems: Hematologic Complications of Illicit Drug Use

In an Education Spotlight Session at this year’s ASH Annual Meeting, experts will be looking at the potentially devastating hematologic complications of illicit drug...
On location

Carfilzomib-Based Quadruplet Regimen Beats Triplet Approach in Newly Diagnosed Myeloma

Induction with the quadruplet regimen of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) led to deeper responses and longer progression-free survival (PFS) in patients with...
On location

Subcutaneous and Intravenous Daratumumab Have Similar Safety, Efficacy in Previously Treated and Newly Diagnosed...

A subcutaneous formulation of daratumumab, plus standard-of-care treatment, led to response rates that were similar to those seen with intravenous daratumumab in patients with...
On location

Can Immunomodulatory Drugs Overcome CHIP’s Effects in Post-Transplant Multiple Myeloma?

Patients with multiple myeloma (MM) who harbor somatic mutations in hematopoietic cells, known as clonal hematopoiesis of indeterminate potential (CHIP), have better post–autologous hematopoietic...
On location

Examining Pregnancy Outcomes in Eculizumab-Treated Women With Atypical Hemolytic Uremic Syndrome

Women with atypical hemolytic uremic syndrome (aHUS) treated with eculizumab have similar pregnancy outcomes to women who were not treated with eculizumab, according to...
On location

Patients With Hemophilia B Report Poor Bleeding Control With Extended Half-Life Factor IX Products

Extended half-life factor IX (FIX) products have been designed to prolong the time between clotting factor injections for patients with hemophilia B, but an...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.